NextPharma Deal Next Step Toward US Distribution of Epigenomics' Colon Cancer Dx

Germany's Epigenomics and life science outsourcing firm NextPharma have signed a global manufacturing contract covering Epi proColon, Epigenomics' nucleic acid amplification-based colorectal cancer screening test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.